NZ606996A - Thorium-227 for use in radiotherapy of soft tissue disease - Google Patents
Thorium-227 for use in radiotherapy of soft tissue diseaseInfo
- Publication number
- NZ606996A NZ606996A NZ606996A NZ60699604A NZ606996A NZ 606996 A NZ606996 A NZ 606996A NZ 606996 A NZ606996 A NZ 606996A NZ 60699604 A NZ60699604 A NZ 60699604A NZ 606996 A NZ606996 A NZ 606996A
- Authority
- NZ
- New Zealand
- Prior art keywords
- thorium
- soft tissue
- radiotherapy
- tissue disease
- excluding
- Prior art date
Links
- ZSLUVFAKFWKJRC-FTXFMUIASA-N thorium-227 Chemical compound [227Th] ZSLUVFAKFWKJRC-FTXFMUIASA-N 0.000 title abstract 3
- 208000016247 Soft tissue disease Diseases 0.000 title 1
- 238000001959 radiotherapy Methods 0.000 title 1
- 230000008685 targeting Effects 0.000 abstract 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 239000008139 complexing agent Substances 0.000 abstract 1
- 229940014144 folate Drugs 0.000 abstract 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 1
- 235000019152 folic acid Nutrition 0.000 abstract 1
- 239000011724 folic acid Substances 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 210000004872 soft tissue Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Radiology & Medical Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Radiation-Therapy Devices (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0308731.9A GB0308731D0 (en) | 2003-04-15 | 2003-04-15 | Method of radiotherapy |
| NZ595758A NZ595758A (en) | 2003-04-15 | 2004-04-15 | Thorium-227 for use in radiotherapy of soft tissue disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ606996A true NZ606996A (en) | 2014-08-29 |
Family
ID=35385222
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ606996A NZ606996A (en) | 2003-04-15 | 2004-04-15 | Thorium-227 for use in radiotherapy of soft tissue disease |
| NZ595758A NZ595758A (en) | 2003-04-15 | 2004-04-15 | Thorium-227 for use in radiotherapy of soft tissue disease |
| NZ543044A NZ543044A (en) | 2003-04-15 | 2004-04-15 | Thorium-227 for use in radiotherapy of soft tissue disease |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ595758A NZ595758A (en) | 2003-04-15 | 2004-04-15 | Thorium-227 for use in radiotherapy of soft tissue disease |
| NZ543044A NZ543044A (en) | 2003-04-15 | 2004-04-15 | Thorium-227 for use in radiotherapy of soft tissue disease |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1617876B1 (https=) |
| JP (2) | JP5006032B2 (https=) |
| KR (2) | KR20060015507A (https=) |
| CN (1) | CN100586484C (https=) |
| AU (1) | AU2004229218B2 (https=) |
| BR (1) | BRPI0409387B8 (https=) |
| CA (1) | CA2522148C (https=) |
| CY (1) | CY1115407T1 (https=) |
| DK (1) | DK1617876T3 (https=) |
| EA (1) | EA008195B1 (https=) |
| ES (1) | ES2486845T3 (https=) |
| IL (1) | IL171148A (https=) |
| MX (1) | MXPA05010804A (https=) |
| NO (1) | NO332931B1 (https=) |
| NZ (3) | NZ606996A (https=) |
| PL (1) | PL1617876T3 (https=) |
| PT (1) | PT1617876E (https=) |
| ZA (1) | ZA200507983B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2522148C (en) * | 2003-04-15 | 2010-07-13 | Algeta As | Thorium-227 for use in radiotherapy of soft tissue disease |
| GB201002508D0 (en) * | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| GB201007354D0 (en) * | 2010-04-30 | 2010-06-16 | Algeta Asa | Method |
| GB201105298D0 (en) * | 2011-03-29 | 2011-05-11 | Algeta Asa | Pharmaceutical preparation |
| GB201600153D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Isotope preparation method |
| GB201600154D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Isotope preparation method |
| ES2952744T3 (es) | 2016-12-15 | 2023-11-03 | Nestle Sa | Composiciones y procedimientos que modulan los glóbulos blancos o los neutrófilos en un animal de compañía |
| FR3088769B1 (fr) * | 2018-11-15 | 2020-12-25 | Orano Med | Procede de preparation d'au moins un generateur a haute teneur en radium-228 |
| RU2767567C1 (ru) * | 2020-10-27 | 2022-03-17 | Станислав Анатольевич Дороватовский | Комплексные соединения, содержащие в своем составе радионуклид 227Th, а также бисфосфонатный фрагмент, способы их получения, а также потенциальное применение в качестве действующего вещества в составе остеотропного радиофармацевтического лекарственного препарата |
| CN119912489B (zh) * | 2024-12-23 | 2026-02-03 | 中国科学院近代物理研究所 | 一种膦酸钍框架材料及其制备方法和在钍镭发生器中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69007430T2 (de) * | 1989-06-19 | 1994-07-07 | Akzo Nobel N.V., Arnheim/Arnhem | Radioimmuntherapie unter alphapartikelausstrahlung. |
| SG52470A1 (en) * | 1992-04-13 | 1998-09-28 | Dow Chemical Co | Process for preparing macrocyclic chelating agents and formation of chelates and conjugates thereof |
| CN1073860C (zh) * | 1998-08-20 | 2001-10-31 | 中国核动力研究设计院 | 用于骨肿瘤治疗或诊断的放射性药物药盒的制备方法 |
| MY133346A (en) * | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| NO314537B1 (no) | 1999-12-06 | 2003-04-07 | Anticancer Therapeutic Inv Sa | Reseptorbindende konjugater |
| NO312708B1 (no) * | 2000-02-21 | 2002-06-24 | Anticancer Therapeutic Inv Sa | Radioaktive liposomer til terapi |
| WO2001066155A2 (en) * | 2000-02-25 | 2001-09-13 | Dangshe Ma | Actinium-225 complexes and conjugates for radioimmunotherapy |
| NO313180B1 (no) * | 2000-07-04 | 2002-08-26 | Anticancer Therapeutic Inv Sa | Bensökende alfapartikkel emitterende radiofarmasöytika |
| ITMI20022411A1 (it) * | 2002-11-14 | 2004-05-15 | Bracco Imaging Spa | Agenti per la diagnosi e la terapia di tumori che espongono sulla superficie delle cellule proteine alterate. |
| CA2522148C (en) * | 2003-04-15 | 2010-07-13 | Algeta As | Thorium-227 for use in radiotherapy of soft tissue disease |
-
2004
- 2004-04-15 CA CA2522148A patent/CA2522148C/en not_active Expired - Lifetime
- 2004-04-15 JP JP2006506137A patent/JP5006032B2/ja not_active Expired - Lifetime
- 2004-04-15 MX MXPA05010804A patent/MXPA05010804A/es active IP Right Grant
- 2004-04-15 AU AU2004229218A patent/AU2004229218B2/en not_active Expired
- 2004-04-15 PT PT47275870T patent/PT1617876E/pt unknown
- 2004-04-15 EA EA200501456A patent/EA008195B1/ru not_active IP Right Cessation
- 2004-04-15 CN CN200480016329A patent/CN100586484C/zh not_active Expired - Lifetime
- 2004-04-15 PL PL04727587T patent/PL1617876T3/pl unknown
- 2004-04-15 KR KR1020057019497A patent/KR20060015507A/ko not_active Ceased
- 2004-04-15 DK DK04727587.0T patent/DK1617876T3/da active
- 2004-04-15 NZ NZ606996A patent/NZ606996A/en not_active IP Right Cessation
- 2004-04-15 BR BRPI0409387A patent/BRPI0409387B8/pt not_active IP Right Cessation
- 2004-04-15 ZA ZA200507983A patent/ZA200507983B/en unknown
- 2004-04-15 EP EP04727587.0A patent/EP1617876B1/en not_active Expired - Lifetime
- 2004-04-15 NZ NZ595758A patent/NZ595758A/xx not_active IP Right Cessation
- 2004-04-15 KR KR1020117003862A patent/KR101274867B1/ko not_active Expired - Lifetime
- 2004-04-15 ES ES04727587.0T patent/ES2486845T3/es not_active Expired - Lifetime
- 2004-04-15 NZ NZ543044A patent/NZ543044A/en not_active IP Right Cessation
-
2005
- 2005-09-28 IL IL171148A patent/IL171148A/en active IP Right Grant
- 2005-11-15 NO NO20055390A patent/NO332931B1/no unknown
-
2011
- 2011-12-02 JP JP2011265169A patent/JP5468597B2/ja not_active Expired - Lifetime
-
2014
- 2014-07-28 CY CY20141100569T patent/CY1115407T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2002102299A3 (en) | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer | |
| NZ527283A (en) | Modified antibodies and methods of use | |
| NO20064676L (no) | Farmasoytiske salter av 3-0-(3'3'-dimetylsuccinyl)betulinsyre | |
| EP1594542A4 (en) | ANTI-CD70 ANTIBODY MEDICAMENT CONJUGATES AND THEIR USE FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | |
| NZ606996A (en) | Thorium-227 for use in radiotherapy of soft tissue disease | |
| NZ611563A (en) | Human antibodies that bind human il-12 and methods for producing | |
| AR048098A1 (es) | Conjugados de caliqueamicina | |
| WO2001082975A3 (en) | Membrane-permeant peptide complexes for medical imaging | |
| WO2000056774A8 (en) | Methods of using bioelastomers | |
| WO2001085204A3 (en) | Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells | |
| DE69942148D1 (de) | Gebrauch von bispezifischen antikörpern in diagnose und therapie | |
| IL172982A0 (en) | Antibodies and ca6 antigen specific cytotoxic conjugates and pharmaceutical compositions containing the same | |
| TR200101673A2 (tr) | Düz kas hücrelerinin sıkışmasıyla ilgili hastalıkların tedavisindeki kompozisyonlar için biyokimyasal maddeler. | |
| NO20021701L (no) | Fremgangsmåte for fremstilling av et konjugat av polyglutamat og et terapeutisk middel | |
| BRPI0411200A (pt) | método de tratamento de cáncer, métodos de tratamento de paciente humano, artigo industrializado e kit de tratamento de cáncer | |
| ATE312635T1 (de) | Ventilanordnung | |
| WO2004032857A3 (en) | Antibody therapy | |
| BRPI0608853B8 (pt) | composições farmacêuticas e processo para a fabricação de microgrânulos de rifaximina gastrorresistentes | |
| CA2534816A1 (en) | Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors | |
| WO2003089593A3 (en) | Adjuvant enhanced immunotherapy | |
| NZ542866A (en) | Compositions and methods for the therapy of inflammatory bowel disease | |
| DK1327146T3 (da) | Forbindelse med et forgrenet linkermolekyle | |
| AU2002352187A8 (en) | Use of laminarin in the treatment of cancer as well as bacterial, viral and fungal infections | |
| WO2002015895A3 (en) | Alpha-difluoromethylornithine (dfmo) use in the human prostate | |
| AU2003244762A1 (en) | Methods and compositions for intravesical therapy of bladder cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 9 YEARS UNTIL 15 APR 2017 BY BALDWINS INTELLECTUAL PROPERTY Effective date: 20150303 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 APR 2018 BY CPA GLOBAL Effective date: 20170318 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 APR 2019 BY CPA GLOBAL Effective date: 20180322 |
|
| LAPS | Patent lapsed |